Immatics enters into a strategic partnership with Genmab

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced that it has entered into a research collaboration and license agreement with Genmab, a publicly traded biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. The companies will conduct joint research, funded by Genmab, to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancer indications. Under the terms of the agreement, Immatics will receive an upfront fee of 54m USA and is eligible to receive up to 550m USD in milestone payments and tiered royalties up to a double-digit percentage of net sales. Read more here.